Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1995 1
1996 1
1997 1
1998 4
1999 13
2000 31
2001 69
2002 120
2003 157
2004 212
2005 252
2006 246
2007 322
2008 337
2009 317
2010 329
2011 326
2012 340
2013 340
2014 328
2015 286
2016 285
2017 311
2018 310
2019 270
2020 108
Text availability
Article attribute
Article type
Publication date

Search Results

4,684 results
Results by year
Filters applied: . Clear all
Page 1
Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events.
Subedi S, Gong Y, Chen Y, Shi Y. Subedi S, et al. Drug Des Devel Ther. 2019 Jul 23;13:2491-2502. doi: 10.2147/DDDT.S200147. eCollection 2019. Drug Des Devel Ther. 2019. PMID: 31413544 Free PMC article. Review.
Lack of adherence to infliximab therapy is mainly due to loss of response (LOR) over time and adverse events, particularly because infusion reactions are usually encountered. ...This review discusses the efficacy of infliximab as demonstrated by various clini …
Lack of adherence to infliximab therapy is mainly due to loss of response (LOR) over time and adverse events, particularly bec …
Infliximab-Related Infusion Reactions: Systematic Review.
Lichtenstein L, Ron Y, Kivity S, Ben-Horin S, Israeli E, Fraser GM, Dotan I, Chowers Y, Confino-Cohen R, Weiss B. Lichtenstein L, et al. J Crohns Colitis. 2015 Sep;9(9):806-15. doi: 10.1093/ecco-jcc/jjv096. Epub 2015 Jun 19. J Crohns Colitis. 2015. PMID: 26092578 Free PMC article. Review.
OBJECTIVE: Administration of infliximab is associated with a well-recognised risk of infusion reactions. ...The aim of this study is to perform a systematic review of the evidence behind the strategies for preventing infusion reactions to infliximab, and for control …
OBJECTIVE: Administration of infliximab is associated with a well-recognised risk of infusion reactions. ...The aim of this study is …
Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease.
Hemperly A, Vande Casteele N. Hemperly A, et al. Clin Pharmacokinet. 2018 Aug;57(8):929-942. doi: 10.1007/s40262-017-0627-0. Clin Pharmacokinet. 2018. PMID: 29330783 Review.
Infliximab was the first monoclonal antibody to be approved for the treatment of pediatric and adult patients with moderately to severely active Crohn's disease (CD) and ulcerative colitis (UC). ...Median infliximab half-life is approximately 14 days. Infl
Infliximab was the first monoclonal antibody to be approved for the treatment of pediatric and adult patients with moderately to seve
Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?
Murdaca G, Spanò F, Contatore M, Guastalla A, Penza E, Magnani O, Puppo F. Murdaca G, et al. Expert Opin Drug Saf. 2016 Jan;15(1):43-52. doi: 10.1517/14740338.2016.1112375. Epub 2015 Nov 11. Expert Opin Drug Saf. 2016. PMID: 26559805 Review.
There are several TNF-alpha inhibitors available for clinical use including infliximab, adalimumab, golimumab, certolizumab pegol and etanercept. AREAS COVERED: infliximab and adalimumab can induce the development of anti-infliximab (anti-IFX) and anti-adalim …
There are several TNF-alpha inhibitors available for clinical use including infliximab, adalimumab, golimumab, certolizumab pegol and …
The pharmacotherapeutic management of pediatric Crohn's disease.
Zimmerman L, Bousvaros A. Zimmerman L, et al. Expert Opin Pharmacother. 2019 Dec;20(17):2161-2168. doi: 10.1080/14656566.2019.1659778. Epub 2019 Oct 1. Expert Opin Pharmacother. 2019. PMID: 31574236 Review.
Introduction: Crohn's disease (CD) is a chronic inflammatory condition that can occur throughout the gastrointestinal tract. The aims of treatment of children with CD are to induce and maintain clinical remission of disease, optimize nutrition and growth, minimize adver
Introduction: Crohn's disease (CD) is a chronic inflammatory condition that can occur throughout the gastrointestinal tract. The aims …
Inflammatory Bowel Disease in Childhood and Adolescence.
Däbritz J, Gerner P, Enninger A, Claßen M, Radke M. Däbritz J, et al. Dtsch Arztebl Int. 2017 May 12;114(19):331-338. doi: 10.3238/arztebl.2017.0331. Dtsch Arztebl Int. 2017. PMID: 28597827 Free PMC article. Review.
In Crohn's disease, exclusive enteral nutrition is the treatment of first choice for inducing a remission. ...Specific aspects of the treatment of children and adolescents with IBD include adverse drug effects, the areas of nutrition, growth, and development, …
In Crohn's disease, exclusive enteral nutrition is the treatment of first choice for inducing a remission. ...Specific aspects of the …
Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence Study.
Meyer A, Rudant J, Drouin J, Weill A, Carbonnel F, Coste J. Meyer A, et al. Ann Intern Med. 2019 Jan 15;170(2):99-107. doi: 10.7326/M18-1512. Epub 2018 Dec 11. Ann Intern Med. 2019. PMID: 30534946 Clinical Trial.
BACKGROUND: CT-P13 is a biosimilar of the reference product (RP) infliximab, with demonstrated efficacy and safety for some inflammatory arthritides. It was approved for the treatment of Crohn disease (CD) on that basis, without specific studies examining its effects
BACKGROUND: CT-P13 is a biosimilar of the reference product (RP) infliximab, with demonstrated efficacy and safety for some inflammat …
Review of pulmonary adverse effects of infliximab therapy in Crohn's disease.
Patel D, Madani S, Patel S, Guglani L. Patel D, et al. Expert Opin Drug Saf. 2016 Jun;15(6):769-75. doi: 10.1517/14740338.2016.1160053. Epub 2016 Mar 16. Expert Opin Drug Saf. 2016. PMID: 26923135 Review.
This article summarizes the literature related to pulmonary adverse effects of Infliximab therapy in Crohn's Disease. AREA COVERED: Published reports of specific pulmonary complications during ongoing therapy with infliximab in patients with IBD …
This article summarizes the literature related to pulmonary adverse effects of Infliximab therapy in Crohn's Dis …
Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series.
Gelfand JM, Bradshaw MJ, Stern BJ, Clifford DB, Wang Y, Cho TA, Koth LL, Hauser SL, Dierkhising J, Vu N, Sriram S, Moses H, Bagnato F, Kaufmann JA, Ammah DJ, Yohannes TH, Hamblin MJ, Venna N, Green AJ, Pawate S. Gelfand JM, et al. Neurology. 2017 Nov 14;89(20):2092-2100. doi: 10.1212/WNL.0000000000004644. Epub 2017 Oct 13. Neurology. 2017. PMID: 29030454 Free PMC article.
OBJECTIVE: To describe clinical and imaging responses in neurosarcoidosis to infliximab, a monoclonal antibody against tumor necrosis factor-alpha. ...RESULTS: Of 66 patients with CNS sarcoidosis (27 definite, 39 probable) treated with infliximab for a median of 1.5 …
OBJECTIVE: To describe clinical and imaging responses in neurosarcoidosis to infliximab, a monoclonal antibody against tumor necrosis …
Immune Checkpoint Inhibitors-Induced Colitis.
Tian Y, Abu-Sbeih H, Wang Y. Tian Y, et al. Adv Exp Med Biol. 2018;995:151-157. doi: 10.1007/978-3-030-02505-2_7. Adv Exp Med Biol. 2018. PMID: 30539510 Review.
Immune checkpoint inhibitors (ICIs) have shown significant benefit in cancer patients, but are associated with immune-related adverse events (irAEs), that can affect the gastrointestinal tract resulting in diarrhea and colitis. ...Current management strategy is mainly anti …
Immune checkpoint inhibitors (ICIs) have shown significant benefit in cancer patients, but are associated with immune-related adverse
4,684 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback